KDventures gains NCE protection through 2042, broadening commercial upside
A Redeye analyst published a Research Note on KDventures, highlighting that Umecrine Secured NCE protection through 2042.
Redeye’s analyst published a Research Note on KDventures. Click here to read the article. Make sure to add KDventures to your Watchlist at Redeye so analysts can notify you if anything relevant happens regarding the company. About Redeye Nordic Growth AB.